Estimaciones de analistas de Wall Street para Enveric Biosciences, Inc. (ENVB): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 3 |
| Mantener | 1 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 4 |
| Calificación media (1-5) | 0.75 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-12 | |||
| 2026-08-14 | $-0.76 | ||
| 2026-05-15 | $-1.08 | ||
| 2026-03-27 | $0.85 | $-55.80 | +101.5% |
| 2025-11-14 | $-10.81 | $-63.00 | +82.8% |
| 2025-08-11 | $-11.64 | $-63.00 | +81.5% |
| 2025-05-13 | $-14.64 | $-72.00 | +79.7% |
| 2025-03-31 | $-57.96 | $-3.45 | -1580.0% |
Ratios de valoración
| Precio / Valor contable | 0.74 |
| EV / EBITDA | 0.87 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $36.1M | $48.6M | $43.0M | $39.9M | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $29.6M | $38.4M | $34.0M | $31.8M | $120872 | $681612 | $435201 | $408030 | $337489 | $200858 |
| Beneficio Bruto | $6.5M | $10.2M | $9.0M | $8.2M | -$120872 | -$681612 | -$435201 | -$408030 | -$337489 | -$200858 |
| I+D | 0 | 0 | 0 | 0 | $174083 | $4.8M | $8.0M | $7.3M | $2.8M | $2.8M |
| Generales y Administrativos | $9.0M | $18.5M | $10.8M | $12.2M | $5.3M | $20.5M | $11.5M | $8.8M | $6.5M | $5.8M |
| Gastos Operativos | $10.3M | $21.7M | $13.7M | $14.5M | $5.5M | $25.3M | $19.5M | $16.0M | $9.3M | $8.6M |
| Beneficio Operativo | -$5.4M | -$12.0M | -$7.1M | -$6.3M | -$5.6M | -$25.9M | -$20.0M | -$16.4M | -$9.6M | -$8.8M |
| EBITDA | -$4.4M | -$7.7M | -$6.9M | -$2.3M | -$6.3M | -$55.7M | -$19.5M | -$16.9M | -$9.2M | -$8.6M |
| Gastos por Intereses | $751074 | $575039 | $729896 | $691138 | $445250 | $10316 | $5249 | $3708 | 0 | $106 |
| Beneficio Antes de Impuestos | -$6.5M | -$11.5M | -$10.5M | -$5.2M | -$6.9M | -$56.4M | -$20.0M | -$17.3M | -$9.6M | -$8.8M |
| Impuestos | -$3.7M | -$2.4M | $6.3M | $388657 | 0 | -$7.5M | -$1.5M | $28913 | $8930 | $3.4M |
| Beneficio Neto | -$2.8M | -$9.1M | -$16.9M | -$5.6M | -$6.9M | -$49.0M | -$18.5M | -$17292 | -$9.6M | -$12.1M |
| BPA | $-12770.04 | $-36347.76 | $-42616.68 | $-2543.88 | $-666.00 | $-1244.28 | $-156.00 | $-97.08 | $-228.48 | $-36.24 |
| BPA Diluido | $-12770.04 | $-36347.76 | $-42616.68 | $-2543.88 | $-666.00 | $-1244.28 | $-156.00 | $-97.08 | $-228.48 | $-36.24 |
| Acciones en Circulación (Diluidas) | $218 | $250 | $396 | $2203 | $9589 | $39362 | $173189 | $179922 | $41908 | $334719 |
Precio
| Precio | $1.49 |
| Capitalización | $1M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: AZTR · HEPA · INDP · JSPR · ONCO · SCNI · SLRX
Explorar sector: Healthcare · Biotechnology
Más secciones de ENVB: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones